Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac

Lancet Infect Dis. 2021 Aug;21(8):1071-1072. doi: 10.1016/S1473-3099(21)00287-5. Epub 2021 May 27.
No abstract available

Publication types

  • Letter
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Neutralizing / blood
  • Antibodies, Neutralizing / immunology*
  • Antibodies, Neutralizing / isolation & purification
  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology*
  • Antibodies, Viral / isolation & purification
  • COVID-19 / immunology
  • COVID-19 / prevention & control*
  • COVID-19 / virology
  • COVID-19 Vaccines / administration & dosage
  • COVID-19 Vaccines / immunology*
  • China
  • Female
  • HEK293 Cells
  • Healthy Volunteers
  • Humans
  • Immunogenicity, Vaccine
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Mutation
  • Prospective Studies
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / immunology*
  • Spike Glycoprotein, Coronavirus / genetics
  • Spike Glycoprotein, Coronavirus / immunology
  • Treatment Outcome
  • Vaccines, Inactivated / administration & dosage
  • Vaccines, Inactivated / immunology*
  • Young Adult

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19 Vaccines
  • SARS-CoV-2 inactivated vaccines
  • Spike Glycoprotein, Coronavirus
  • Vaccines, Inactivated
  • spike protein, SARS-CoV-2